Search Results

You are looking at 1 - 10 of 7,484 items for :

  • "recurrence" x
Clear All
Restricted access

Ken Ishii, Kazuhiro Chiba, Masahiko Watanabe, Hiroo Yabe, Yoshikazu Fujimura and Yoshiaki Toyama

C hordoma is a rare malignant tumor that originates from the remnants of the notochord and is seen in close relation to the axial skeleton. In most cases it is located in the sacrococcygeal area and, somewhat less frequently, in the sphenooccipital or cervical area. The tumor grows slowly yet is locally aggressive and has a high recurrence rate. 2, 9, 15 Although the treatment of choice is excision, 3, 7 it is often impossible to achieve radical resection because of the lesion's complicated anatomical location, especially in the sacrococcygeal area. Over the

Restricted access

Yoshihiro Minamida, Takeshi Mikami, Kazuo Hashi and Kiyohiro Houkin

S urgical management of craniopharyngioma, despite its histologically benign nature, remains challenging because of the tumor's proximity to vital structures, including the optic apparatus, pituitary stalk, hypothalamus, and vessels in the circle of Willis. In addition, the high frequency of this tumor's recurrence and regrowth is a challenge for neurosurgeons during long-term follow-up periods. Various strategies have been advocated to improve outcomes in patients with craniopharyngiomas. Some neurosurgeons have stressed total removal of the tumor without

Free access

Tanmoy K. Maiti, Shyamal C. Bir, Devi Prasad Patra, Piyush Kalakoti, Bharat Guthikonda and Anil Nanda

S pinal meningiomas are common, slow-growing tumors with a known association with neurofibromatosis Type 2 (NF2). They account for 25%–45% of all intradural spinal tumors and about 2% of all meningiomas. 33 However, they can be extradural, dumbbell shaped, or en plaque type. Safe, complete resection is possible in most cases, with a favorable outcome. Although few studies have discussed the factors predicting recurrence, composite studies of multiple clinicoradiological factors predicting the resection rate, recurrence, and functional outcome in a cohort

Restricted access

The prediction of recurrence in meningiomas

A flow cytometric study of paraffin-embedded archival material

Paul L. May, John C. Broome, John Lawry, Robert A. Buxton and Robert D. E. Battersby

T he recurrence rate of meningiomas after surgical treatment is dependent on the extent of surgical resection and the rate of tumor regrowth. 14 Since total macroscopic removal is assessed visually by the surgeon and recurrence rates between 9% and 32% are reported in patients in whom there has been “complete excision” along with dura and abnormal bone, 17, 19 it must be assumed that in some proportion of “total surgical excisions” viable meningioma cells remain. The rate of regrowth of these cells determines the rate of clinical and radiological recurrence

Free access

David Dornbos III, Constantine L. Karras, Nicole Wenger, Blake Priddy, Patrick Youssef, Shahid M. Nimjee and Ciarán J. Powers

subtypes. In addition to treatment of unruptured large, broad-necked aneurysms, several studies have evaluated the use of PEDs in the treatment of aneurysm recurrence following prior treatment with endovascular or open microsurgical modalities. One of the greatest pitfalls in the treatment of intracranial aneurysms with standard coils or stent-assisted coiling is the high recurrence rate, with recurrence rates of 13%–48% and retreatment in up to 13% of previously coiled aneurysms. 4 , 13 , 24 Microsurgical clipping is largely regarded as the most robust option

Restricted access

Andrew B. Adegbite, Moe I. Khan, Kenneth W. E. Paine and Leonard K. Tan

recurrence is significantly influenced by the grade of the operation; the more radical the excision, the smaller the chance of recurrence. 2, 5, 6, 9–12 The role of radiation therapy, however, remains controversial. Most authors suggest postoperative radiotherapy in cases where excision is incomplete, where the tumor is malignant, or in cases of recurrent tumors. 1, 4, 8, 12 Preoperative radiotherapy, presumably for highly vascular tumors, and radiation therapy as the primary treatment, have few proponents. 1 We review our experience in the management of 114 patients

Restricted access

R. Michael Scott and H. Thomas Ballantine Jr.

as a well-differentiated glioma. H & E, X 400. Examination In April, 1971, 3 months after recurrence of symptoms, the patient was readmitted to the Massachusetts General Hospital. The previous craniectomy site was well healed and firmly calcified. The pupils were nonreactive, and the patient had no light perception in either eye. He could not maintain a full right lateral gaze, because the eyes drifted back to the midline. There was marked truncal ataxia when sitting or standing. Finger to nose and heel to shin testing revealed bilateral ataxia, greater

Free access

Andreas Stadlbauer, Ilker Eyüpoglu, Michael Buchfelder, Arnd Dörfler, Max Zimmermann, Gertraud Heinz and Stefan Oberndorfer

Neovascularization in GB has high clinical relevance as it correlates with biological aggressiveness, degree of malignancy, clinical recurrence, and postoperative survival. 8 Despite ongoing progress in the therapeutic management of GB, the prognosis remains poor, with an overall survival (OS) of 14–15 months after maximum radical and safe resection, concomitant radiochemotherapy, and adjuvant chemotherapy. 35 A main reason for the poor prognosis is the fact that GB treatment failure and recurrence are as yet inevitable and typically occur 6–7 months after surgery. Gross

Full access

Timothy R. Smith, David J. Cote, John A. Jane Jr. and Edward R. Laws Jr.

, and radiation oncology. Major questions exist regarding the optimal surgical goals (for example, gross-total resection vs subtotal resection followed by adjuvant therapy), the ideal timing and modality of radiation therapy, and the role of pituitary hormone replacement therapy. 5 Some studies have reported that physiological growth hormone (GH) replacement after resection of craniopharyngioma may increase the recurrence rate of these lesions, while others indicate that GH replacement is safe and effective. 9 , 11 , 22 , 27 , 31 , 46 The Genentech National

Full access

Peter Adamczyk, Arun Paul Amar, William J. Mack and Donald W. Larsen

embolizations performed using Onyx (ev3 Neurovascular), a novel ethylene vinyl alcohol copolymer preparation with low viscosity and delayed precipitation. 30 While many authors have reported high curative rates, the long-term durability of such treatments remains uncertain as DAVF recurrence has been observed in patients after successful treatment. 9 , 13 , 27 We report 3 cases of apparent cure of intracranial and spinal DAVFs that developed subsequent recanalization despite the documented presence of Onyx in the draining vein, and we review the literature for DAVF